Charles E. Geyer, MD, FACP, discusses dosing strategies and adverse event management with olaparib.
Charles E. Geyer, MD, FACP
Advertisement
Articles by Charles E. Geyer, MD, FACP
Advertisement
Latest Updated Articles
Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast CancerPublished: March 28th 2022 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
NGS Streamlines Biomarker Testing in Solid Tumors
2
An NP’s Perspective: Supporting Derm Toxicities in Breast Cancer as a Team
3
Solo Sevabertinib Shows Durable Activity in HER2+ NSCLC
4
Osimertinib/Chemo Boosts OS in EGFR+ NSCLC With Poor Prognosis
5
